Evaluation of p53, Ki67, IMP3 and P504S in the adjuvant diagnosis of gastric epithelial neoplasia by biopsy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022725

Enrollment

Unknown

Registered

2019-04-23

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Gastri Cancer

Interventions

Gold Standard:Postoperative pathology

Index test:Four&#32

immunohistochemical&#32

indices:&#32

p53,&#32

Ki67,&#32

IMP3,&#32

P504S

Eligibility

Sex/Gender

All

Age

51 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who underwent gastric submucosal resection in our hospital from January 2015 to March 2019; 2. Postoperative pathological diagnosis is gastric low-grade intraepithelial neoplasia or early gastric cancer (including high-grade intraepithelial neoplasia).

Exclusion criteria

Exclusion criteria: 1. Patients who received preoperative chemotherapy and radiotherapy; 2. Patients with other malignant tumors.

Design outcomes

Primary

Measure	Time frame
p53 gene;Ki 67 proliferation index;P504S;IMP3;	—

Countries

China

Contacts

Public ContactLi Feng

leowind1984@sina.com+86 13918303471

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026